Funa K, Gazdar A F, Mattson K, Niiranen A, Koivuniemi A, Oberg K, Wilander E, Doyle A, Linnoila R I
Clin Immunol Immunopathol. 1986 Oct;41(1):159-64. doi: 10.1016/0090-1229(86)90060-7.
Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and beta 2-microglobulin, beta 2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced beta 2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining beta 2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-alpha therapy. Before IFN treatment, 3/4 SCLC tumors and 5/7 mid-gut carcinoids did not express beta 2m. By contrast, all tumors showed considerable expression of beta 2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.
某些神经内分泌肿瘤，如小细胞肺癌（SCLC）和神经母细胞瘤，表达明显减少的I类主要组织相容性复合体（MHC）抗原（HLA框架和β2微球蛋白，β2m）。本文证实，另一种神经内分泌肿瘤——中肠类癌，也表达减少的β2m抗原。通过体外暴露于干扰素（IFN），SCLC细胞系上的抗原表达大大增强。为了确定IFN在体内是否介导类似作用，我们通过免疫过氧化物酶染色检查了4例SCLC患者和7例中肠类癌患者在接受部分纯化的人白细胞IFN-α治疗前后石蜡包埋肿瘤组织切片中的β2m表达。在IFN治疗前，4例SCLC肿瘤中有3例、7例中肠类癌中有5例不表达β2m。相比之下，所有肿瘤在IFN治疗后均显示出β2m的大量表达。在缺乏此类表达的肿瘤细胞上诱导I类抗原可能是IFN发挥抗肿瘤作用的一种机制。我们认为这是关于人类上皮肿瘤细胞中I类MHC抗原体内诱导的首次报道。
